A cooperative network of molecular "hot spots" highlights the complexity of LH3 collagen glycosyltransferase activities

Antonella Chiapparino[1,*,#] , Francesca De Giorgi[1,*], Luigi Scietti[1,]*, Silvia Faravelli[1], Tony Roscioli[2,3,4], Federico Forneris[1]

[1] *The Armenise-Harvard Laboratory of Structural Biology, Dept. Biology and Biotechnology - University of Pavia, via Ferrata 9, 27100 Pavia, Italy, http://fornerislab.unipv.it;*
[2] *NSW Health Pathology East laboratory, Prince of Wales Hospital, Randwick, NSW, Australia;*
[3] *Centre for Clinical Genetics, Sydney Children's Hospital, Randwick, Australia;*
[4] *Neuroscience Research Australia (NeuRA), Prince of Wales Clinical School, University of New South Wales, Sydney, Australia*

* These authors contributed equally to this work.

[#] *Present address: Heidelberg University Biochemistry Center (BZH), INF 328, D-69120 Heidelberg, Germany.*

Correspondence to: Federico Forneris (federico.forneris@unipv.it)

Running title: Mechanisms of LH3 glycosyltransferase

Keywords: Collagen biosynthesis; collagen glycosylations; extracellular matrix; post-translational modifications; glycosyltransferase.

ABSTRACT

Hydroxylysine glycosylations are collagen-specific post-translational modifications essential for

maturation and homeostasis of fibrillar as well as non-fibrillar collagen molecules. Lysyl

hydroxylase 3 (LH3) is the only human enzyme capable of performing two chemically-distinct

collagen glycosyltransferase reactions using the same catalytic site: inverting beta-1,O-

galactosylation of hydroxylysines and retaining alpha-1,2-glycosylation of galactosyl

hydroxylysines.

Here, we used structure-based mutagenesis to show that both glycosyltransferase activities are

strongly dependent on a broad cooperative network of amino acid side chains which includes the

first-shell environment of the glycosyltransferase catalytic site and shares features with both

retaining and inverting enzymes. We identified critical "hot spots" leading to selective loss of

inverting activity without affecting the retaining reaction. Finally, we present molecular

structures of LH3 in complex with UDP-sugar analogs which provide the first structural

templates for LH3 glycosyltransferase inhibitor development.

Collectively, our data provide a comprehensive overview of the complex network of shapes,

charges and interactions that enable LH3 glycosyltransferase activities, expanding the molecular

framework for the manipulation of glycosyltransferase functions in biomedical applications.

1. INTRODUCTION

Collagens are the most abundant proteins in the human body and are highly conserved from sponges to mammals (Luther et al, 2011; Myllyharju & Kivirikko, 2004). The different oligomeric architectures and roles of collagen molecules strongly depend on a variety of post-translational modifications, including proline and lysine hydroxylations, as well highly specific glycosylations of hydroxylated lysines (HyK) (Cummings, 2009; Myllyharju & Kivirikko, 2004). The disaccharide present on HyK contains a highly conserved glucosyl(α−1,2)-galactosyl(β−1,O) glycan moiety, whose identity was discovered in the late sixties (Spiro & Spiro, 1971; Spiro, 1967; Spiro, 1969). Monosaccaridic galactosyl-(β−1,O) HyK have been identified as well, as a result of catabolic reactions carried out by the collagen α-glucosidase, an enzyme highly specific for the disaccharide present on collagenous domains. The role for this enzyme is to localize collagen in the glomerular basement membrane (Hamazaki & Hamazaki, 2016; Sternberg et al, 1982; Sternberg & Spiro, 1980).

The spread of glycosylation largely depends on collagen type (Bornstein & Sage, 1980; Spiro, 1969; Terajima et al, 2014), on the functional area inside tissues (Moro et al, 2000; Schofield et al, 1971; Toole et al, 1972), on the developmental stage (Rautavuoma et al, 2004; Sipila et al, 2007) and on disease states (Lehmann et al, 1995; Salo et al, 2008; Tenni et al, 1993). Although extensively studied, the precise mechanisms of collagen glycosylation and their biological relevance in collagen homeostasis have remained poorly understood.

The identity and exquisite stereochemistry of the Glc(α−1,2)-Gal(β−1,O)-HyK-linked carbohydrate supports the idea that at least two distinct enzyme types are needed to fully incorporate these complex post-translational modifications on collagen molecules (Hennet, 2019). The first reaction indeed requires an inverting-type galactosyltransferase (GalT) acting on

HyK, whereas the subsequent glucosylation is catalyzed by a retaining-type

glucosylgalactosyltransferase (GlcT). Multifunctional lysyl hydroxylase 3 (LH3) was the only

enzyme identified as possessing lysyl hydroxylase activity as well as GalT and GlcT activities *in*

vitro (Wang et al, 2002a). The glycosyltransferase activities are specific of LH3, as highly

homologous LH1 and LH2a/b are not capable of catalyzing these reactions (Heikkinen et al,

2000). Conversely, *in vivo* studies have demonstrated that decreased LH3 protein levels and/or

pathogenic mutations in LH3 GT domain, exclusively impair the GlcT activity (Ewans et al,

2019; Salo et al, 2008; Savolainen et al, 1981). This occurs secondarily to the LH3 p.Asn223Ser,

which introduces an additional glycosylation site within the enzyme's GT domain leading to an

osteogenesis imperfecta-like phenotype (Salo et al, 2008); and in the recently identified LH3

p.Pro270Leu, which results in a Stickler-like syndrome with vascular complications and variable

features typical of Ehlers-Danlos syndrome and Epidermolysis Bullosa (Ewans et al, 2019).

Mouse studies have also shown that only the LH3 GlcT activity is indispensable for the

biosynthesis of collagen IV and formation of the basement membrane during embryonic

development (Rautavuoma et al, 2004; Ruotsalainen et al, 2006), consistent with the presence of

additional collagen galactosyltransferases. Two genes encoding for O-galactosyltransferases

(*GLT25D1* and *GLT25D2*) were recently identified (Perrin-Tricaud et al, 2011; Schegg et al,

2009). It is of interest that GLT25D1 and LH3 were proposed to act in concert on collagen

molecules (Schegg et al, 2009; Sricholpech et al, 2011; Yamauchi & Sricholpech, 2012). Studies

on osteosarcoma cell lines which produce large amounts of fibrillar collagens, showed that the

simultaneous deletion of *GLT25D1* and *GLT25D2* resulted in growth arrest due to lack of

glycosylation, further indicating that the GalT activity of LH3 might not be as essential as its

GlcT activity (Baumann & Hennet, 2016).

These data support the existence of a specific and highly conserved machinery for collagen O-

glycosylation, and sustain the hypothesis that *in vivo* the entire collagen glycosylation machinery

may involve distinct proteins and protein complexes for GalT and GlcT reactions. This raises the

intriguing question of how this highly conserved process is spatiotemporally regulated at the

molecular level. Our current understanding of collagen glycosyltransferases is however restricted

to three-dimensional structures of human LH3 in complex with UDP-sugar donor substrates

(Scietti et al, 2018) and to few mutagenesis studies focusing on the main hallmarks of Mn^{2+}-

dependent glycosyltransferase catalysis (Wang et al, 2002a; Wang et al, 2002b).

Here, we combine site-directed mutagenesis scanning with biochemistry and structural biology to

characterize the mechanisms of the two distinct human LH3 glycosyltransferase activities. Our

data highlight an overall distribution of "hot spots" around the extended glycosyltransferase

cavity of LH3, critically involved in both GalT and GlcT functions, but also amino acid residues

capable of selectively abolishing transfer of galactose to HyK without affecting GlcT activity.

Finally, we also identify and characterize UDP-sugar substrate analogs acting as inhibitors of

LH3 glycosyltransferase activities.

Together, our results provide a detailed molecular blueprint of LH3 glycosyltransferase activities

and a structural framework for the development of the first collagen GalT/GlcT inhibitors. These

insights will assist with the manipulation of LH3 protein functions and donor substrate specificity

in biomedical applications.

RESULTS

Features and roles of the non-conserved LH3 "glycoloop"

The LH3 N-terminal GT domain shares its fold with Mn^{2+}-dependent GT-A glycosyltransferases,

encompassing a UDP-donor substrate binding cavity stretched towards a GalT/GlcT catalytic

pocket (Scietti et al, 2018). We firstly inspected the structural organization of the UDP binding

cavity to identify signatures for LH3 glycosyltransferase activity by comparing the amino acid

sequences for the residues surrounding the UDP-sugar donor substrate with those of GalT/GlcT-

inactive LH1 and LH2a/b isoforms. We found that nearly all residues involved in Mn^{2+} and UDP-

sugar binding are conserved in orthologs, with the exception of Val80, becoming Lys68 in LH1

and Gly80 in LH2a/b (Figure 1). The presence of a different amino acid side chain surrounding

the donor substrate cavity led us to consider whether this could be a discriminating functional

feature among the GT domains in LH enzymes. In LH3, Val80 is located in the middle of a

flexible "glycoloop" (Gly72-Gly87), not visible in the electron density of the ligand-free LH3

structure and stabilized upon UDP-substrate binding (Scietti et al, 2018). Within the glycoloop,

residue Val80 is in close proximity to the ribose ring of the UDP-sugar donor substrates. We

hypothesized that introduction of a large, positively charged residue such as Lys in LH1, or

alterations due to complete removal of side chain steric hindrance such as Gly in LH2 could lead

to inability of binding donor substrates. We therefore generated the LH3 Val80Lys mutant. This

enzyme variant was found to be folded based on analytical gel filtration and differential scanning

fluorimetry (DSF), and showed lysine hydroxylation activity comparable to wild-type LH3

(Figure EV1). Conversely, the mutation resulted in a strong impairment of both GalT and GlcT

activities, with 30% and 50% residual activity, respectively when the reaction was carried out in

presence of both donor and acceptor (gelatin) substrates (Figure 2, Appendix Table S1).

Considering that wild-type LH3 is also capable of activating donor UDP-sugar substrates and

release UDP in absence of the acceptor collagen substrate (Scietti et al, 2018), we investigated

the impact of the Val80Lys mutation in absence of acceptor substrates. The experiments yielded

comparable enzymatic activities between wild-type and mutant LH3 (Figure 2, Appendix Table

S1), indicating that this residue might be involved in the productive positioning of the donor

substrate during transfer of the glycan moiety to the acceptor substrate, rather than stabilizing the

UDP moiety in the catalytic pocket.

To further rationalize the implications of LH3 Val80 in GalT and GlcT activities, we crystallized

and solved the 3.0-Å resolution structure of this mutant in complex with Mn^{2+}, and also obtained

the 2.3-Å resolution structure of LH3 Val80Lys mutant in presence of both Mn^{2+} and the UDP-

Glc donor substrate (Appendix Table S2). Overall, both structures superimpose almost perfectly

with wild-type LH3 for all domains (Figure EV2). The structure of the LH3 Val80Lys mutant

bound to Mn^{2+} appeared identical to that of wild-type LH3. In both structures, the glycoloop

containing Val/Lys80 could not be modelled in the electron density due to its high flexibility

(Figure EV2B). On the other hand, the side chain of the Val80Lys residue could be modelled

unambiguously in the experimental electron density of the UDP-donor substrate bound structure

(Figure 3A). Despite the increased steric hindrance, the mutated Lys80 residue adopted a

conformation compatible with the simultaneous presence of the UDP-Glc in the catalytic cavity.

However, similar to what observed for wild-type LH3, the glycan moiety of UDP-Glc was

completely flexible and therefore not visible in the electron density (Figure 3A). Collectively,

these data are consistent with the alteration introduced by the Val80Lys mutation impacting

partially on the LH3 glycosyltransferase catalytic activities

The glycoloop is a structural feature found exclusively in the GT domains of LH enzymes. It

incorporates Trp75, a residue whose aromatic side chain stabilizes the uridine moiety of the

donor substrate and, together with residue Tyr114 of the DxxD motif (a distinguishing feature of

LH3 GT domain, shared among LH enzymes, (Scietti et al, 2018)) "sandwiches" the donor

substrate in an aromatic stacking environment (Figure 1A). Both residues are critical for the LH3

GalT and GlcT enzymatic activities (Scietti et al, 2018). The conformation adopted by the LH3

glycoloop in the presence of UDP-donor substrates is however not accompanied by other

significant structural changes in surrounding amino acids, with the exception of minor

rearrangements of distant residue Trp92 (not conserved in other LH isoenzymes (Figure 1A-B)),

whose bulky side chain rearranges pointing towards the aromatic ring of Trp75. Prompted by this

observation, we mutated this residue to alanine and found that the presence of this variant did not

alter the folding of the enzyme (Figure EV1A-B) nor its LH enzymatic activity (Figure EV1C).

Conversely, the mutant showed 40% decrease for both GalT and GlcT activities in presence of

donor and acceptor substrate compared to LH3 wild-type (Figure 2, Appendix Table S1); the

impact of the Trp92Ala mutation on reactions in absence of acceptor substrate seemed to affect

both activities at similar levels, with slightly stronger reduction in GalT (70%) compared to GlcT

(60%) (Figure 2, Appendix Table S1). These findings suggest that LH3-specific long-range

interactions in the GT domain may contribute to the productive conformations of the glycoloop in

donor substrate-bound states.

In UDP-sugar bound structures, the glycoloop contacts a poly-Asp sequence (Asp188-Asp191,

Figure 1A); this sequence is partially conserved in LH isoforms lacking glycosyltransferase

activities (Figure 1B). Mutations of Asp190 and Asp191 were reported to affect the

glycosyltransferase enzymatic activities of LH3 (Wang et al, 2002b). Based on LH3 crystal

structures, such behaviour is expected, since residues Asp190 and Asp191 point towards the

GalT/GlcT catalytic cavity. Interestingly, superposition of LH3 molecular structures with GT-A

fold glycosyltransferases show that Asp191 caps the N-terminal end of an α-helix in a highly

conserved position, with functional relevance in both retaining (Flint et al, 2005; Persson et al,

2001) and inverting enzymes (Charnock & Davies, 1999; Pedersen et al, 2000) (Figure EV3,

Table 1).

Collectively, these data point towards an involvement of the poly-Asp repeat, and in particular

Asp190 and Asp191, in the positioning and recognition of donor or acceptor substrates.

LH3 shares features with both retaining and inverting glycosyltransferases

After investigating the amino acid residues involved in stabilization of the UDP moiety of donor

substrates, we focused on another group of residues within the GT catalytic pocket, opposite to

the putative position of the flexible sugar rings of the same substrates (Figure 1A). Many LH3

residues shaping this part of the glycosyltransferase catalytic cavity matched catalytic amino

acids found in other GT-A type glycosyltransferases (Figure 1A, Figure EV3) (Ardevol et al,

2016; Lairson et al, 2008). In particular, LH3 Trp145, a residue located in one of the loops of the

GT domain uniquely found in LH3, was previously suggested as a possible candidate for

modulation of LH3 GalT and GlcT activities. This residue was found to adopt different side chain

conformations in substrate-free and substrate-bound structures, affecting the shape and steric

hindrance of the enzyme's catalytic cavity (Scietti et al, 2018); interestingly, nearly identical

conformational changes were observed when comparing substrate-free and substrate bound LH3

Val80Lys structures (Figure 3B). Mutating the LH3 Trp145 residue into alanine strongly reduced

both GalT (6% residual) and GlcT (10% residual) enzymatic activities (Figure 2, Appendix Table

S1), without affecting other enzyme's properties (Figure EV1). This supports previous

hypotheses of a "gating" role for Trp145 in the GT catalytic cavity, assisting the productive

positioning of sugar moieties of donor substrates for effective transfer during catalysis.

Comparison with molecular structures of other glycosyltransferases (including distant homologs)

highlighted that most structurally-related enzymes position aromatic side chains from different

structural elements of their fold in their catalytic cavities in a structural arrangement reminiscent

to that of Trp145 in LH3. In particular, similar aromatic residues were found in other

glycosyltransferases such as Tyr186 in LgtC from *Neisseria meningitidis*, Trp314 in the N-

acetyllactosaminide α-1,3-galactosyl transferase GGTA1, Trp300 in the histo-blood group ABO

system transferase, and Trp243 and Phe245 in the two glucoronyltransferases B3GAT3 and

B3GAT1, respectively (Table 1, Figure EV3). This is surprising, considering that the loop

encompassing residues 142-163 is a unique structural feature of LH3 (Scietti et al, 2018). This

supports glycosyltransferases being highly versatile enzymes, displaying an impressive structural

plasticity to carry out reactions characterized by a very similar mechanism on a large variety of

specific donor and acceptor substrates.

Our previous structural comparisons of ligand-free and substrate-bound LH3 highlighted the

additional possibility of a concerted mechanism involving conformational changes of a non-

conserved aromatic residue located on the LH3 surface (Trp148, Figure 1), together with Trp145

(Scietti et al, 2018). To investigate such possibility, we mutated Trp148 into alanine. The mutant

enzyme was also found to behave like wild-type LH3 in folding and LH activity (Figure EV1).

Glycosyltransferase assays showed that this variant had reduced GalT (30% residual) and GlcT

(50% residual) activities compared to the wild-type, in presence of both donor and acceptor

substrates (Figure 2, Appendix Table S1). Despite the less pronounced alterations than those

observed when mutating Trp145, these data are consistent with possible synergistic mechanisms

between long-range substrate recognition on the enzyme's surface and conformational

rearrangements upon substrate binding in the enzyme's catalytic site.

Molecular structures of LH3 in complex with UDP-Glc and Mn^{2+}, showed weak electron density

near the UDP pyrophosphate group partially compatible with glycan donor substrates, likely

representative of multiple conformations simultaneously trapped in the substrate binding cavity

(Scietti et al, 2018). We explored the LH3 catalytic cavity in its proximity, looking for additional

amino acids potentially critical for catalysis. In particular, we searched for residues carrying

carboxylic or amide side chains, thus capable of acting as candidate catalytic nucleophiles for the

formation of a (covalent) glycosyl-enzyme intermediate prior to glycosylation of the acceptor

substrate (Gloster, 2014).

In retaining-type glycosyltransferases belonging to the GT-6 family, a conserved glutamate has

been found to act as a nucleophile (Albesa-Jove et al, 2017; Coutinho et al, 2003; Lombard et al,

2014). In LH3 structures, we noticed that residue Glu141 points towards the cavity that

accommodates the glycan moiety (Figure 1A). Removal of this carboxylate side chain resulted in

a folded enzyme (Figure EV1) completely deprived of both GalT and GlcT activities (Figure 2,

Appendix Table S1). These data are consistent with the catalytic role of the glutamate proposed

to act as a nucleophile (Albesa-Jove et al, 2017), suggesting that LH3 may indeed act through

similar mechanisms of donor substrate processing, despite the fact that in LH3 Glu141 occupies a

different position within the catalytic cavity when compared to GT-6 glycosyltransferases (Figure

EV3) (Albesa-Jove et al, 2017; Gomez et al, 2012; Patenaude et al, 2002).

Proximate to Glu141 in the GalT/GlcT cavity, residue Asn255 is the closest amino acid to the

UDP phosphate-sugar bond. Despite being fully conserved in LH isoforms (Figure 1B), it is not

found in any GT-A-type glycosyltransferases with known structures to date. The side chain of

Asn255 consistently points to a direction opposite to the donor substrate in all LH3 structures

(Figure 3B, Figure EV2B). We wondered whether the side chain amide group might be involved

in catalysis, possibly through recognition of acceptor substrates given the conformation displayed

by this side chain. Surprisingly, LH3 Asn255Ala mutants showed that their GalT activity was

completely abolished, whereas the GlcT enzymatic activity was reduced to 50% (Figure 2,

Appendix Table S1); the protein was properly folded and showed LH activity comparable to LH3

wild-type (Figure EV1). These results identify Asn255 as a possible critical discriminating

residue for the two glycosyltransferase activities of LH3, and rule out possible functions for this

residue as catalytic nucleophile for retaining-type glycosyltransferase mechanisms, given its

major impact restricted to the GalT catalytic activity.

Pathogenic LH3 mutations in the LH3 GT domain affect protein folding

Recently a new pathogenic LH3 mutation, Pro270Leu, has been identified and mapped at the

interface of the AC and GT domain (Ewans et al, 2019). This residue localizes in a loop which is

critical for shaping the GT cavity, although given its position it is unlikely to play direct roles in

catalysis. To better understand the impact of this pathogenic mutation on LH3 enzymatic activity,

we generated a Pro270Leu mutant. In this case, due to very low expression levels, we could not

reliably carry out any *in vitro* investigations. Considering the high reproducibility associated to

recombinant production of a large variety of LH3 point mutants, this result may indicate that this

mutation is likely to severely impact the overall enzyme stability rather than its enzymatic

activity, resulting in extremely low protein expression levels *in vitro* and likely also *in vivo*.

Molecular structures of LH3 in complex with UDP-sugar analogs provide insights on how glycan

moieties are processed inside the LH3 catalytic cavity

A frequent limitation associated to molecular characterizations of glycosyltransferases is the high

flexibility of the donor substrate glycan moiety within the catalytic cavity. Such limitation

becomes even more relevant when the enzyme is capable of processing UDP-sugar molecules in

absence of acceptor substrates, such as in the case of LH3. Considering our previous (Scietti et al,

2018) and current co-crystallization results, we wondered whether free UDP, the product of the

enzymatic reaction, could remain bound in the LH3 GT domain with the same efficiency as

physiological donor substrates even after processing. We therefore compared the binding of free

UDP and donor UDP-sugars using DSF and detected a thermal shift of 3.5 °C for free UDP,

compared to a 2-2.5 °C shift using UDP-sugar substrates (Figure 4A). These results suggested

that free UDP may bind to LH3, likely with even higher affinity than UDP-glycan substrates, and

that the GalT and GlcT reactions may therefore be affected by product inhibition. To our surprise,

the increase in thermal stability did not correlate with efficient trapping of the reaction product in

LH3 molecular structures. Independently from the UDP concentration used in co-crystallization

and soaking experiments, we never observed any electron density for free UDP, yielding LH3

structures completely identical to ligand-free enzyme (Figure EV4A).

A report from Kivirikko and colleagues (Kivirikko & Myllyla, 1979) suggested that UDP-

glucuronic acid (UDP-GlcA) could act as competitive inhibitor of collagen glycosyltransferases.

Based on that, UDP-GlcA was used to isolate LH3 from chicken embryos preparation (Myllyla et

al, 1977; Wang et al, 2002a). However, no follow-up biochemical studies could be found in the

literature. We used DSF and luminescence-based GalT and GlcT activity assays to investigate

whether and how UDP-GlcA could affect LH3 enzymatic activity. DSF showed that UDP-GlcA

indeed binds weakly to LH3, resulting in a thermal shift of 1-1.5 °C (Figure 4A), highlighting

limited stabilization compared to UDP-glycan substrates and free UDP. Enzymatic assays also

confirmed the competitive inhibition displayed by this molecule (Figure 4B), with IC_{50} values in

the millimolar range (Appendix Table S1). We also successfully co-crystallized and determined

the 2.2-Å resolution crystal structure of wild-type LH3 in complex with Mn^{2+} and UDP-GlcA

(Appendix Table S2), and found that the inhibitor could efficiently replace UDP-sugar donor

substrates in the substrate cavity (Figure 4C). We observed additional electron density for the

glucuronic acid moiety of the inhibitor in the enzyme's catalytic cavity, however this density

could not be interpreted with a single inhibitor conformation. Nevertheless, analysis of the

experimental electron density for the glucuronic acid moiety unambiguously showed that the

inhibitor adopts a bent conformation: the glycan moiety is deeply buried in the enzyme's catalytic

cavity proximate to residues Lys89, Asp190, Asp191, but distant from the residues found critical

for catalysis, including Trp145, Asn255 and Glu141 (Figure 4C), thereby leaving the remaining

space in the cavity for accommodating acceptor substrates.

Considering the possible conformations adopted by the glucuronic acid moiety based on analysis

of the electron density and the close proximity of the glucuronic acid moiety to LH3 Val80, we

wondered whether the LH3 Val80Lys mutation could interfere with inhibitor binding. We

therefore co-crystallized and solved the 2.7-Å resolution structure of LH3 Val80Lys mutant in

complex with UDP-GlcA (Appendix Table S2), and surprisingly observed partial displacement of

the glycoloop, for which we could not observe the typical well defined electron density present in

UDP-sugar-bound wild-type LH3 structures (Figure 4D). At the same time, we could not observe

improvements in the quality of the electron density for the glucuronic acid moiety, resulting even

poorer than what observed in wild-type LH3 (Figure 4D). This suggests that the intrinsic

flexibility of the sugar-like moiety is not influenced by specific conformations of the glycoloop,

but rather by lack of specific protein-ligand interactions that could provide stabilization of the

sugar ring in a unique structural arrangement.

The lack of a precise conformation for the glucuronic acid moiety observed crystal structures

prompted us for a further investigation of another UDP-sugar substrate analog, characterized by

lack of the carboxylic moiety of UDP-GlcA: UDP-Xylose (UDP-Xyl). Similar to UDP-GlcA,

UDP-Xyl resulted to be a weak inhibitor of LH3 GalT and GlcT activities (Figure 4A-B), with

IC$_{50}$ in the high micromolar range (Appendix Table S1). The 2.0-Å resolution structure of LH3 in

complex with Mn^{2+} and UDP-Xyl also showed the inhibitor bound inside the enzyme's catalytic

cavity, with weak electron density associated to the sugar moiety suggesting multiple

conformations of the xylose moiety attached to UDP, similar to what observed for UDP-GlcA

(Figure 4E). Taken together, these results suggest that the LH3 GT binding cavity is capable of

hosting a variety of UDP-sugar substrates, and that inhibition likely depends on the reduced

flexibility (and therefore increased stabilization) of the ligand within the cavity. In this respect,

we could expect that UDP-sugar analogs strongly interacting with side chains proximate to the

glycan moieties of UDP-GlcA and UDP-Xyl, may have the potential to become powerful

inhibitors of LH3 glycosyltransferase activities.

DISCUSSION

Glycosyltransferases are highly versatile, yet very specific enzymes. If carefully inspected, they

reveal a series of recurrent features that allow their comparative characterization even in presence

of very low sequence/structure conservation. LH3 has been known for long time as a

promiscuous enzyme able to exploit both an inverting and a retaining catalytic mechanism *in*

vitro for the specific transfer of different sugars to at least two different acceptor substrates: the

HyK and the GalHyK of collagens (Myllyharju & Kivirikko, 2004). Our *in vitro* investigations

highlight multiple hot spots important for LH3 glycosyltransferase activity: the glycoloop, the

poly-Asp helix, the acceptor substrate cavity, and the region proximate to the UDP-sugar donor

substrate (Figure 1A).

LH3 is the only isoform of its family found capable of glycosyltransferase activities, however the

strong sequence conservation among human LH isoforms cannot be used to elucidate the key

determinants for this additional function. The GT domain has features (such as the DxxD motif,

the poly-Asp region, the glycoloop) not found in other glycosyltransferases, yet highly conserved

within the LH family (Figure 1B). Computational homology models of homologous LH1 and

LH2a/b (Scietti et al, 2019) (Suppl. Fig. 5) support the possibility of UDP-sugar donor binding

and processing. To fully investigate LH enzymes' GT domains, we focused on the only non-

matching residue present within the whole amino acid sequence directly surrounding the UDP-

donor substrate. This residue (Val80 in LH3, corresponding to Lys68 in LH1 and Gly80 in

LH2a/b) is located in the middle of the glycoloop, in close proximity to the ribose ring of the

UDP-sugar donor substrate(s). Our data were consistent with this residue being important for

catalysis, as it assists the positioning of the bound donor substrate and in particular the glycan

moiety. However, the results also emphasize how sequence alterations at this site are not

sufficient to justify the lack of GalT/GlcT enzymatic activities in homologous LH1/2. We

therefore expanded our investigation to the second-shell environment surrounding the donor

substrate, and found that non-conserved LH3 Trp92 (Leu80 in LH1, Leu92 in LH2a/b) positions

its aromatic side chain in a conformation that stabilizes the entire glycoloop to facilitate the

enzymatic reactions. Again, mutating this residue did not lead to full loss of the

glycosyltransferase activities. This is consistent with the loss of GalT/GlcT functions in LH1 and

LH2a/b being associated to a broad set of subtle alterations, possibly involving residues distant

from the actual enzyme's catalytic site, likely essential for recognition of collagen acceptor

substrates.

Prompted by these observations, we expanded our investigation to the LH3 catalytic cavity

expected to host the glycan moieties of the UDP-sugar donor substrates and the acceptor

molecules. Residues Asp190 and Asp191 of the characteristic LH3 poly-Asp helix lie in a

conserved position compared to other retaining and inverting type GT-A (Figure EV3, Table 1)

and their carboxylate moieties are critical for catalysis (Wang et al, 2002b). Although residues

matching these positions have been proposed to act as catalytic nucleophiles in retaining type

GT-A (Flint et al, 2005; Persson et al, 2001; Wang et al, 2002b), and as catalytic bases in

inverting type GT-A (Charnock & Davies, 1999; Pedersen et al, 2000), their distances and the

relative orientations with respect to UDP-sugar donor substrates in the LH3 GT domain (Figure

1A) do not support this hypothesis. Nevertheless, these residues play critical roles in recognizing

and assisting the proper positioning of donor UDP-sugar substrates, as shown by their proximity

to glycan moieties in LH3 co-crystal structures with UDP-sugar analogs (Figure 4C-E), a feature

observed also in mutagenesis studies on other GT-A retaining type glycosyltransferases (Lairson

et al, 2004).

On the opposite site of the UDP-binding pocket, LH3 exhibits a non-conserved loop shaping the

GT catalytic cavity bearing two aromatic residues, the Trp145 and the Trp148 that seem to act in

a concerted way during catalysis, as suggested by comparisons between substrate-free and

substrate-bound LH3 molecular structures (Figure 1A). Trp145 is indispensable for both

GalT/GlcT activities: its conformational changes seem to respond to the presence and

conformational positioning of the donor substrate inside the catalytic cavity. Although located in

a loop that is uniquely found in LH3, the Trp145 side chain matches a site frequently occupied by

bulky aromatic residues in other GT-A glycosyltransferases that shape a portion of the GT cavity

to facilitate donor substrate processing and catalysis. This further highlights the versatility of

glycosyltransferases, in which many different structural features have evolved to specifically

recognize distinct donor and acceptor substrates, while preserving the ability to carry out the

same catalytic reaction. The implication in catalysis of the less conserved Trp148 on the surface

of the GT domain is even more intriguing: this residue seems to coordinately respond to the

rearrangements of its counterpart Trp145 in the catalytic site, suggesting involvement in

recognition of the acceptor substrate prior to its access into the GT cavity. Alternatively, Trp148

may contribute to long-range stabilizing interactions with collagen molecules, while they dock

their HyK or GalHyK residues in the acceptor substrate site during the GalT or GlcT reactions,

respectively.

Catalytic nucleophiles have been clearly identified so far only in the retaining-type

glycosyltransferases belonging to the GT-6 family (Coutinho et al, 2003; Lombard et al, 2014),

such as the α−1,3 galactosyltransferase (GGTA1) where a conserved glutamate is found

positioned on the β−face of the donor sugar (Albesa-Jove et al, 2017; Gomez et al, 2012;

Patenaude et al, 2002) (Figure EV3). Conversely, extensive structural comparisons and

mutagenesis experiments have been performed in the O-galactosyltransferase LgtC from

Neisseria menengitidis, focusing on matching residue, Gln189 (Lairson et al, 2004). However,

the role of this residue as catalytic nucleophile was ruled out. This site is occupied by Gln192 in

LH3. This residue is next to the poly-Asp helix, distant from the sites occupied by donor

substrates and in an arrangement that is not compatible with a direct role in catalysis. In spite of

that, we identified the carboxylate side chain of LH3 residue Glu141 pointing directly towards

the glycan moiety (Figure 1A), and found that this residue is essential for both GalT and GlcT

activities (Figure 2, Appendix Table S1). Glu141 adopts a conformation corresponding to Asp130

in the O-galactosyltransferase LgtC from *Neisseria meningitidis*, Asp125 in the O-

glucosyltransferase GYG1 from rabbit, and Gln247 in the O-glucosyltransferase GGTA1 from

Bos taurus (Suppl. Fig. 3, Table 1). As the removal of this carboxylate side chain completely

abolishes LH3 glycosyltransferase activities (Figure 2, Appendix Table S1), we suggest that the

site corresponding to Glu141 might be a critical "hot spot" during catalysis in those

glycosyltransferases that present in the same position carboxylate or amide side chains.

Side chain amides are also good candidate nucleophiles. In LH3, residue Asn255 is the closest

amino acid to the UDP phosphate-sugar bond, but in crystal structures its side chain consistently

points to a direction opposite to the donor substrate (Figure 1A). When inspecting the molecular

structures of other GT-A glycosyltransferases, we noticed that this residue is not conserved

(Figure EV3). Strikingly, the LH3 Asn255Ala mutant showed a complete loss of GalT activity,

but partially preserved the GlcT activity. Although the significance of *in vivo* LH3 GalT activity

is uncertain, such activity is clearly detectable *in vitro* (Scietti et al, 2018; Wang et al, 2002a).

The ability of Asn255 to selectively abolish only LH3 GalT activity highlights how LH3 can

promiscuously accept and recognize very different acceptor substrates (i.e., collagen HyK *versus*

GalHyK) within the same catalytic site and carry out two glycosyltransferase reactions with

different mechanisms (i.e., inverting GalT and retaining GlcT). Presently, LH3 is the only known

glycosyltransferase capable of such promiscuity, and our data show that it shares numerous

features with both retaining and inverting glycosyltransferases. Collectively, these results suggest

the intriguing possibility that LH3 is not just the ancestor of the whole LH family, but may

preserve in its sequence features belonging to the evolutionary precursors of both retaining and

inverting glycosyltransferases. In this respect, the carbohydrate-active enzyme (CAZy)

classification (Lombard et al, 2014) requires for enzymes belonging to the same family to carry

out reactions with the same stereochemical outcome. Given the distinguishing features and dual

mode of action observed and now characterized for LH3, we suggest this enzyme as the funding

member of a new family of GT-A glycosyltransferases, the GT-X family.

Our work provides a set of 3D structures of LH3 in complex with UDP-sugar analogs, which

work as mild inhibitors (Figure 4). Despite the high flexibility observed for the glycan moieties of

the bound molecules, the new molecular structures presented provide valuable insights for

structure-based drug development of inhibitors of LH3 GalT/GlcT enzymatic activities. These

molecules may give the spark to innovative therapeutic strategies against pathological conditions

characterized by excess collagen glycosylations, such as osteogenesis imperfecta (Raghunath et

al, 1994).

Together with the mutagenesis scanning of the entire GT catalytic site, our work provides a

comprehensive overview of the complex network of shapes, charges and interactions that enable

LH3 GalT and GlcT activities.

MATERIALS AND METHODS

5.1 Chemicals

All chemicals were purchased from Sigma-Aldrich (Germany) unless otherwise specified.

5.2 Site-directed mutagenesis

The LH3 coding sequence (GenBank accession number BC011674.2 - Source Bioscience),

devoid of the N-terminal signal peptide was amplified using oligonucleotides containing in-frame

5′-BamHI and 3′-NotI (Appendix Table S3) and cloned in a pCR8 vector, that was used as a

template for subsequent mutagenesis experiments. All LH3 mutants were generated using the

Phusion Site Directed Mutagenesis Kit (ThermoFisher Scientific). The entire plasmid was

amplified using phosphorylated primers. For all mutants the forward primer introduced the

mutation of interest (Appendix Table S3). The linear mutagenized plasmid was phosphorylated

prior to ligation. All plasmids were checked by Sanger sequencing prior to cloning into the

expression vector.

5.3 Recombinant protein expression and purification

Wild-type and mutant LH3 coding sequences were cloned into the pUPE.106.08 expression

vector (U-protein Express BV, The Netherlands) in frame with a 6xHis-tag followed by a

Tobacco Etch Virus (TEV) protease cleavage site. Suspension growing HEK293F cells (Life

Technologies, UK) were transfected at a confluence of 10^6 cells ml^{-1}, using 1 μg of plasmid DNA

and 3 μg of linear polyethyleneimine (PEI; Polysciences, Germany). Cells were harvested 6 days

after transfection by centrifuging the medium for 15 minutes at 1000 x *g*. The clarified medium

was filtered using a 0.2 mm syringe filter and the pH was adjusted to 8.0 prior to affinity

purification as previously described (Scietti et al, 2018). All proteins were isolated from the

medium exploiting the affinity of the 6xHis tag for the HisTrap Excel (GE Healthcare, USA)

affinity column. The purified protein was further polished using a Superdex 200 10/300 GL (GE

Healthcare) equilibrated in 25 mM HEPES/NaOH, 200 mM NaCl, pH 8.0, to obtain a

homogenous protein sample; peak fractions containing the protein of interest were pooled and

concentrated to 1 mg mL^{-1}.

5.4 Crystallization, data collection, structure determination and refinement

Wild-type and mutant LH3 co-crystallization experiments were performed using the hanging-

drop vapor-diffusion method protocols as described in (Scietti et al, 2018), by mixing 0.5 μL of

enzyme concentrated at 3.5 mg mL^{-1} with 0.5 μL of reservoir solutions composed of 600 mM

sodium formate, 12% poly-glutamic-acid (PGA-LM, Molecular Dimensions), 100 mM

HEPES/NaOH, pH 7.8, 500 μM $FeCl_2$, 500 μM $MnCl_2$, supplemented with 1 mM of the

appropriate UDP-sugar analogs (UDP, UDP-glucose, UDP-glucuronic acid, UDP-xylose).

Crystals were cryo-protected with the mother liquor supplemented with 20% ethylene glycol,

harvested using MicroMounts Loops (Mitegen), flash-cooled and stored in liquid nitrogen prior

to data acquisition. X-ray diffraction data were collected at various beamlines of the European

Synchrotron Radiation Facility, Grenoble, France and at the Swiss Light Source, Villigen,

Switzerland. Data were indexed and integrated using *XDS* (Kabsch, 2010) and scaled using

Aimless (Evans & Murshudov, 2013). Data collection statistics are summarized in Appendix

Table S2. The data showed strong anisotropy and therefore underwent anisotropic cut-off using

STARANISO (Tickle et al, 2018) prior to structure determination and refinement. The structures

were solved by molecular replacement using the structure of wild-type LH3 in complex with

Fe^{2+}, 2-OG and Mn^{2+} (pdb: 6FXM) (Scietti et al, 2018) as search model using *PHASER* (McCoy

et al, 2007). The structure was refined with successive steps of manual building in *COOT*

(Emsley et al, 2010) and automated refinement with *phenix.refine* (Adams et al, 2010). Model

validation was performed with *MolProbity* (Chen et al, 2010). Refinement statistics for the final

models are reported in Appendix Table S2.

5.5 Evaluation of LH3 GalT/GlcT enzymatic activity

LH, GalT and GlcT activities were tested using luminescence-based enzymatic assays with a

Glomax Discover (Promega, USA) as described in *Scietti et al.* (Scietti et al, 2018). Minor

modifications have been done for GalT/GlcT competitive inhibition assays, where 1 μL of a

miture of 250 μM $MnCl_2$, 500 μM UDP-galactose (GalT assay) or UDP-glucose (GlcT assay)

and increasing concentrations of either UDP-GlcA or UDP-Xyl were initially added to the

enzyme and gelatin substrate to start the reactions. All experiments were performed in triplicates.

Control experiments were performed in the same conditions by selectively removing LH3. Data

were analyzed and plotted using the GraphPad Prism 7 (Graphpad Software, USA)

5.6 Differential Scanning Fluorimetry (DSF)

DSF assays were performed on LH3 wt and mutants using a Tycho NT.6 instrument

(NanoTemper Technologies GmbH, Germany). LH3 samples at a concentration of 1 mg/mL in a

buffer composed of 25 mM HEPES, 500 mM NaCl, pH 8. Binding assays were performed by

incubating LH3 with 50 uM $MnCl_2$ and 5 mM free UDP or UDP-sugar donor substrates or their

analogs. Data were analyzed and plotted using the GraphPad Prism 7 (Graphpad Software, USA).

ACKNOWLEDGEMENTS

We thank the European Synchrotron Radiation Facility (ESRF) and the Swiss Light Source (SLS)

for the provision of synchrotron radiation facilities. We thank Dr. M. Campioni for useful

discussions and M. Miao for support in crystallization experiments. This project has received

funding from the European Union's Horizon 2020 research and innovation program under the

Marie Curie grant agreement COTETHERS - n. 745934 to AC, the Italian Association for Cancer

Research (AIRC, "My First AIRC Grant" id. 20075 to FF), by Fondazione Giovanni Armenise-

Harvard (CDA2013 to FF), and by the Italian Ministry of Education, University and Research

(MIUR): Dipartimenti di Eccellenza Program (2018–2022, to the Dept. of Biology and

Biotechnology "L. Spallanzani", University of Pavia). None of the funding sources had roles in

study design, collection, analysis and interpretation of data, in the writing of the report and in the

decision to submit this article for publication.

AUTHOR CONTRIBUTIONS

AC generated and purified LH3 mutants with support from SF, carried out biochemical

investigations and crystallized LH3 mutants; LS purified and crystallized wild-type LH3 in

complex with UDP-sugar analogs; FDG performed LH3 enzymatic activity assays; LS, FDG and

FF carried out structural refinement and analyses; TR was part of the study group focusing on

LH3 pathogenic variants. FF designed the study with help from AC, FDG and LS. AC and FF

wrote the paper, with contributions from all authors.

CONFLICT OF INTEREST STATEMENT

The authors declare no competing interests.

DATA AVAILABILITY

The atomic coordinates and structure factors described in this work have been deposited in

the Protein Data Bank under accession codes 6TE3, 6TEC, 6TES, 6TEU, 6TEX, 6TEZ.

REFERENCES

Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* **66:** 213-221

Albesa-Jove D, Sainz-Polo MA, Marina A, Guerin ME (2017) Structural Snapshots of alpha-1,3-Galactosyltransferase with Native Substrates: Insight into the Catalytic Mechanism of Retaining Glycosyltransferases. *Angew Chem Int Ed Engl* **56:** 14853-14857

Ardevol A, Iglesias-Fernandez J, Rojas-Cervellera V, Rovira C (2016) The reaction mechanism of retaining glycosyltransferases. *Biochem Soc Trans* **44:** 51-60

Baumann S, Hennet T (2016) Collagen Accumulation in Osteosarcoma Cells lacking GLT25D1 Collagen Galactosyltransferase. *J Biol Chem* **291:** 18514-18524

Bornstein P, Sage H (1980) Structurally distinct collagen types. *Annu Rev Biochem* **49:** 957-1003

Charnock SJ, Davies GJ (1999) Structure of the nucleotide-diphospho-sugar transferase, SpsA from Bacillus subtilis, in native and nucleotide-complexed forms. *Biochemistry* **38:** 6380-6385

Chen VB, Arendall WB, 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW,

Richardson JS, Richardson DC (2010) MolProbity: all-atom structure validation for

macromolecular crystallography. *Acta Crystallogr D Biol Crystallogr* **66:** 12-21

Coutinho PM, Deleury E, Davies GJ, Henrissat B (2003) An evolving hierarchical family

classification for glycosyltransferases. *J Mol Biol* **328:** 307-317

Cummings RD (2009) The repertoire of glycan determinants in the human glycome. *Mol Biosyst*

5: 1087-1104

Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. *Acta*

Crystallographica Section D **66:** 486-501

Evans PR, Murshudov GN (2013) How good are my data and what is the resolution? *Acta*

Crystallogr D Biol Crystallogr **69:** 1204-1214

Ewans LJ, Colley A, Gaston-Massuet C, Gualtieri A, Cowley MJ, McCabe MJ, Anand D, Lachke

SA, Scietti L, Forneris F, Zhu Y, Ying K, Walsh C, Kirk EP, Miller D, Giunta C, Sillence D,

Dinger M, Buckley M, Roscioli T (2019) Pathogenic variants in PLOD3 result in a Stickler

syndrome-like connective tissue disorder with vascular complications. *J Med Genet*

Flint J, Taylor E, Yang M, Bolam DN, Tailford LE, Martinez-Fleites C, Dodson EJ, Davis BG,

Gilbert HJ, Davies GJ (2005) Structural dissection and high-throughput screening of

mannosylglycerate synthase. *Nat Struct Mol Biol* **12:** 608-614

Gloster TM (2014) Advances in understanding glycosyltransferases from a structural perspective.

Curr Opin Struct Biol **28:** 131-141

Gomez H, Lluch JM, Masgrau L (2012) Essential role of glutamate 317 in galactosyl transfer by

alpha3GalT: a computational study. *Carbohydr Res* **356:** 204-208

Hamazaki H, Hamazaki MH (2016) Catalytic site of human protein-
glucosylgalactosylhydroxylysine glucosidase: Three crucial carboxyl residues were determined
by cloning and site-directed mutagenesis. *Biochem Biophys Res Commun* **469:** 357-362

Heikkinen J, Risteli M, Wang C, Latvala J, Rossi M, Valtavaara M, Myllyla R (2000) Lysyl
hydroxylase 3 is a multifunctional protein possessing collagen glucosyltransferase activity. *J Biol*
Chem **275:** 36158-36163

Hennet T (2019) Collagen glycosylation. *Curr Opin Struct Biol* **56:** 131-138

Kabsch W (2010) Xds. *Acta Crystallogr D Biol Crystallogr* **66:** 125-132

Kivirikko KI, Myllyla R (1979) Collagen glycosyltransferases. *Int Rev Connect Tissue Res* **8:** 23-
72

Lairson LL, Chiu CP, Ly HD, He S, Wakarchuk WW, Strynadka NC, Withers SG (2004)
Intermediate trapping on a mutant retaining alpha-galactosyltransferase identifies an unexpected
aspartate residue. *J Biol Chem* **279:** 28339-28344

Lairson LL, Henrissat B, Davies GJ, Withers SG (2008) Glycosyltransferases: structures,
functions, and mechanisms. *Annu Rev Biochem* **77:** 521-555

Lehmann HW, Wolf E, Roser K, Bodo M, Delling G, Muller PK (1995) Composition and
posttranslational modification of individual collagen chains from osteosarcomas and osteofibrous
dysplasias. *J Cancer Res Clin Oncol* **121:** 413-418

Lombard V, Golaconda Ramulu H, Drula E, Coutinho PM, Henrissat B (2014) The carbohydrate-
active enzymes database (CAZy) in 2013. *Nucleic Acids Res* **42:** D490-495

Luther KB, Hulsmeier AJ, Schegg B, Deuber SA, Raoult D, Hennet T (2011) Mimivirus collagen

is modified by bifunctional lysyl hydroxylase and glycosyltransferase enzyme. *J Biol Chem* **286:**

43701-43709

McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ (2007) Phaser

crystallographic software. *J Appl Crystallogr* **40:** 658-674

Moro L, Romanello M, Favia A, Lamanna MP, Lozupone E (2000) Posttranslational

modifications of bone collagen type I are related to the function of rat femoral regions. *Calcif*

Tissue Int **66:** 151-156

Myllyharju J, Kivirikko KI (2004) Collagens, modifying enzymes and their mutations in humans,

flies and worms. *Trends Genet* **20:** 33-43

Myllyla R, Anttinen H, Risteli L, Kivirikko KI (1977) Isolation of collagen glucosyltransferase as

a homogeneous protein from chick embryos. *Biochim Biophys Acta* **480:** 113-121

Patenaude SI, Seto NO, Borisova SN, Szpacenko A, Marcus SL, Palcic MM, Evans SV (2002)

The structural basis for specificity in human ABO(H) blood group biosynthesis. *Nat Struct Biol*

9: 685-690

Pedersen LC, Tsuchida K, Kitagawa H, Sugahara K, Darden TA, Negishi M (2000)

Heparan/chondroitin sulfate biosynthesis. Structure and mechanism of human

glucuronyltransferase I. *J Biol Chem* **275:** 34580-34585

Perrin-Tricaud C, Rutschmann C, Hennet T (2011) Identification of domains and amino acids

essential to the collagen galactosyltransferase activity of GLT25D1. *PLoS One* **6:** e29390

Persson K, Ly HD, Dieckelmann M, Wakarchuk WW, Withers SG, Strynadka NC (2001) Crystal

structure of the retaining galactosyltransferase LgtC from Neisseria meningitidis in complex with

donor and acceptor sugar analogs. *Nat Struct Biol* **8:** 166-175

Raghunath M, Bruckner P, Steinmann B (1994) Delayed triple helix formation of mutant

collagen from patients with osteogenesis imperfecta. *J Mol Biol* **236:** 940-949

Rautavuoma K, Takaluoma K, Sormunen R, Myllyharju J, Kivirikko KI, Soininen R (2004)

Premature aggregation of type IV collagen and early lethality in lysyl hydroxylase 3 null mice.

Proc Natl Acad Sci U S A **101:** 14120-14125

Ruotsalainen H, Sipila L, Vapola M, Sormunen R, Salo AM, Uitto L, Mercer DK, Robins SP,

Risteli M, Aszodi A, Fassler R, Myllyla R (2006) Glycosylation catalyzed by lysyl hydroxylase 3

is essential for basement membranes. *J Cell Sci* **119:** 625-635

Salo AM, Cox H, Farndon P, Moss C, Grindulis H, Risteli M, Robins SP, Myllyla R (2008) A

connective tissue disorder caused by mutations of the lysyl hydroxylase 3 gene. *Am J Hum Genet*

83: 495-503

Savolainen ER, Kero M, Pihlajaniemi T, Kivirikko KI (1981) Deficiency of

galactosylhydroxylysyl glucosyltransferase, an enzyme of collagen synthesis, in a family with

dominant epidermolysis bullosa simplex. *N Engl J Med* **304:** 197-204

Schegg B, Hulsmeier AJ, Rutschmann C, Maag C, Hennet T (2009) Core glycosylation of

collagen is initiated by two beta(1-O)galactosyltransferases. *Mol Cell Biol* **29:** 943-952

Schofield JD, Freeman IL, Jackson DS (1971) The isolation, and amino acid and carbohydrate

composition, of polymeric collagens prepared from various human tissues. *Biochem J* **124:** 467-

473

Scietti L, Campioni M, Forneris F (2019) SiMPLOD, a structure-integrated database of collagen

lysyl hydroxylase (LH/PLOD) enzyme variants. *J Bone Miner Res*

Scietti L, Chiapparino A, De Giorgi F, Fumagalli M, Khoriauli L, Nergadze S, Basu S, Olieric V,

Cucca L, Banushi B, Profumo A, Giulotto E, Gissen P, Forneris F (2018) Molecular architecture

of the multifunctional collagen lysyl hydroxylase and glycosyltransferase LH3. *Nat Commun* **9:**

3163

Sipila L, Ruotsalainen H, Sormunen R, Baker NL, Lamande SR, Vapola M, Wang C, Sado Y,

Aszodi A, Myllyla R (2007) Secretion and assembly of type IV and VI collagens depend on

glycosylation of hydroxylysines. *J Biol Chem* **282:** 33381-33388

Spiro MJ, Spiro RG (1971) Studies on the biosynthesis of the hydroxylsine-linked disaccharide

unit of basement membranes and collagens. II. Kidney galactosyltransferase. *J Biol Chem* **246:**

4910-4918

Spiro RG (1967) The structure of the disaccharide unit of the renal glomerular basement

membrane. *J Biol Chem* **242:** 4813-4823

Spiro RG (1969) Characterization and quantitative determination of the hydroxylysine-linked

carbohydrate units of several collagens. *J Biol Chem* **244:** 602-612

Sricholpech M, Perdivara I, Nagaoka H, Yokoyama M, Tomer KB, Yamauchi M (2011) Lysyl

hydroxylase 3 glucosylates galactosylhydroxylysine residues in type I collagen in osteoblast

culture. *J Biol Chem* **286:** 8846-8856

Sternberg M, Grochulski A, Peyroux J, Hirbec G, Poirier J (1982) Studies on the alpha-

glucosidase specific for collagen disaccharide units: variations associated with capillary basement

membrane thickening in kidney and brain of diabetic and aged rats. *Coll Relat Res* **2:** 495-506

Sternberg M, Spiro RG (1980) Studies on the catabolism of the hydroxylysine-linked

disaccharide units of basement membranes and collagens: isolation and characterization of a new

rat-kidney alpha-glucosidase of high specificity. *Ren Physiol* **3:** 1-3

Tenni R, Valli M, Rossi A, Cetta G (1993) Possible role of overglycosylation in the type I

collagen triple helical domain in the molecular pathogenesis of osteogenesis imperfecta. *Am J*

Med Genet **45:** 252-256

Terajima M, Perdivara I, Sricholpech M, Deguchi Y, Pleshko N, Tomer KB, Yamauchi M (2014)

Glycosylation and cross-linking in bone type I collagen. *J Biol Chem* **289:** 22636-22647

Tickle IJ, Flensburg C, Keller P, Paciorek W, Sharff A, Vonrhein C, Bricogne G. (2018)

STARANISO. Global Phasing Ltd. , Cambridge, United Kingdom.

Toole BP, Kang AH, Trelstad RL, Gross J (1972) Collagen heterogeneity within different growth

regions of long bones of rachitic and non-rachitic chicks. *Biochem J* **127:** 715-720

Wang C, Luosujarvi H, Heikkinen J, Risteli M, Uitto L, Myllyla R (2002a) The third activity for

lysyl hydroxylase 3: galactosylation of hydroxylysyl residues in collagens in vitro. *Matrix Biol*

21: 559-566

Wang C, Risteli M, Heikkinen J, Hussa AK, Uitto L, Myllyla R (2002b) Identification of amino

acids important for the catalytic activity of the collagen glucosyltransferase associated with the

multifunctional lysyl hydroxylase 3 (LH3). *J Biol Chem* **277:** 18568-18573

Yamauchi M, Sricholpech M (2012) Lysine post-translational modifications of collagen. *Essays*

Biochem **52:** 113-133

 FIGURE LEGENDS

 Figure 1: Features of the LH3 glycosyltransferase (GT) domain. (A) Cartoon representation

 of the LH3 GT domain (PDB ID: 6FXR) showing the key residues shaping the catalytic site as

 sticks. The PolyAsp motif (brown) and the Glycoloop (cyan) involved in binding of UDP-sugar

 donor substrates are shown. The residues implicated in the catalytic activity and investigated in

 this works are colored, while the residues depicted in grey have already been shown to be

 essential in Mn^{2+} (purple sphere) and UDP (black sticks) coordination. (B) Sequence alignment

 of human LH1, LH2 and LH3 GT domains, highlighting similarities and differences in the

 aminoacid residues within the active site. Residues shown in Figure 1A are indicated with a

 triangle. Colored boxes indicate the PolyAsp motif (brown) and the Glycoloop (cyan).

 Figure 2: Evaluation of the effect of LH3 GT domain mutations in the GT site on

 glycosyltransferase activities. Evaluation of the GalT activity (A) and GlcT activity (B) of LH3

 mutants compared to the wild-type. The plotted data are baseline-corrected, where the baseline

 was the background control.

 Figure 3. Structural characterization of the LH3 Val80Lys mutant. (A) Crystal structure of

 the LH3 Val80Lys mutant in complex with UDP-glucose and Mn^{2+}. Electron density is visible

 for the mutated lysine and the UDP donor substrate (green mesh, $2F_o$-F_c omit electron density

 map, contoured at 1.3 σ). Catalytic residues shaping the enzyme cavity are shown as sticks, Mn^{2+}

 is shown as purple sphere. Consistent with what observed in the crystal structure of wild-type

 LH3, the glucose moiety of the donor substrate is not visible in the experimental electron density.

 (B) Superposition of wild-type and Val80Lys LH3 crystal structures in substrate-free (cyan and

yellow, respectively) with UDP-glucose bound (marine and orange, respectively) states. Notably,

the conformations adopted by the side chain of Trp145 upon ligand binding are consistent in the

wild-type and in the mutant enzyme. As the glycoloop is flexible in substrate-free structures, the

side chains of Val/Lys80 are visible only in the in UDP-sugar bound structures.

Figure 4. Characterization of UDP-sugar analogs. (A) Thermal stability of LH3 wild-type

(solid green) using differential scanning fluorimetry (DSF) in presence of various Mn^{2+} and

several UDP-sugars. A prominent stabilization effect is achieved in presence of the biological

donor substrates UDP-galactose (solid blue), UDP-Glucose (solid purple) and free UDP (solid

black). A milder stabilization effect is also obtained with UDP-xylose (red dash) and UDP-

glucuronic acid (green dash). (B) Evaluation of GalT and GlcT enzymatic activities of LH3 in the

presence of increasing concentrations of UDP-GlcA or UDP-Xyl. (C) Crystal structure of LH3

wild-type in complex with Mn^{2+} and UDP-glucuronic acid shows clear electron density for UDP

($2F_o$-F_c omit electron density maps, green mesh, contour level 1.2 σ). The glucuronic acid

(shown in yellow) can be modelled even if with partial electron density. (D) Crystal structure of

the LH3 Val80Lys mutant in complex with Mn^{2+} and UDP-glucuronic acid. Whereas the UDP

backbone can be modelled in the electron density (black sticks) ($2F_o$-F_c omit electron density

maps, green mesh, contour level 1.2 σ), in this case no electron density is present for the

glucuronic acid (shown in yellow). In addition, the portion of the glycoloop containing the

mutated lysine is flexible from residue 79 to 83 (shown as cyan spheres). (E) Crystal structure of

LH3 wild-type in complex with Mn^{2+} and UDP-xylose. Similarly to UDP-GlcA, UDP shows

clear electron density ($2F_o$-F_c omit electron density maps, green mesh, contour level 1.2 σ),

whereas partial density is shown for the xylose moiety (shown in pink).

Table 1: List of glycosyltransferase enzymes used for comparisons with human LH3. The

list includes the indication of the catalytic bases and nucleophile residues as proposed in the

original papers describing the various glycosyltransferases, with the corresponding residue

number in human LH3 based on structural superpositions.

Protein Name	Type	PDB ID	catalytic base residue	nucleophile acceptor residue	corresp. LH3 residue	reference paper
LgtC - GALACTOSYL TRANSFERASE LGTC (*N. meningitidis*)	retaining	1GA8				Persson et al., 2001 10.1038/84168
GYG1 - Glycogenin (*O. cuniculus*)	retaining	1LL2		Asp163	Asp191	Gibbons et al., 2002 10.1016/S0022-2836(02)00305-4
mgs - Mannosylglycerate synthase (*R. marinus*)	retaining	2BO8				Flint et al., 2005 10.1038/nsmb950
GALNT10 - Polypeptide N-acetylgalactosaminyl transferase 10 (*H. sapiens*)	retaining	2D7R		Gln346	Asp190	Kubota et al., 2006 10.1016/j.jmb.2006.03.061
GGTA1 - N-Acetyllactosaminide α-1,3-galactosyl transferase (R365K) (*B. taurus*)	retaining	5NRB		Glu317	Gln192	Albesa-Jove et al., 2017 10.1002/anie.201707922
ABO - Histo-blood group ABO system transferase (*H. sapiens*)	retaining	1LZI		Glu303	Gln192	Patenaude et al., 2002 10.1038/nsb832
spsA - PROTEIN (SPORE COAT POLYSACCHARIDE BIOSYNTHESIS PROTEIN SPSA)	inverting	1QGQ	Asp191		Asp191	Charnock et al., 1999 10.1128/JB.183.1.77-85.2001
MGAT1 - N-acetylglucosaminyl transferase I (*O. cuniculus*)	inverting	1FOA	Asp 291		Asp191	Unligil et al., 2000 10.1093/emboj/19.20.5269
Mfng - Manic Fringe glycosyltransferase (*M. musculus*)	inverting	2J0B	Asp 232		Asp191	Jinek et al., 2006 10.1038/nsmb1144
B3GAT3 - GLUCURONYLTRANSFERASE I	inverting	1FGG	Glu281		Asp190	Pedersen et al., 2000 10.1074/jbc.M007399200
B3GAT1 – Galactosylgalactosylxylosyl protein 3-beta-glucuronosyltransferase 1		1V84				Kakuda et al., 2004 10.1074/jbc.M400622200

 EXPANDED VIEW FIGURE LEGENDS

Figure EV1: Biochemical evaluation of the folding state of LH3 wild-type and mutants.

(A) Analytical size-exclusion chromatography analysis comparing wt and mutants LH3.

(B) DSF comparing wt and mutants LH3. The dashed lines indicate the temperature range

incorporating the calculated T_m values for all curves. (C) LH activity comparison for wt and

mutants LH3.

Figure EV2: Comparison of the LH3 wild-type and the LH3 V80K mutant structures in

complex with UDP-glucose. (A) The overall structure superposition of the wild-type LH3 (blue)

and Val80Lys mutant (orange) shows that the two structures are almost identical. (B) Zoomed

view of the GT active site of the two structures shown in (A), indicating that the sole difference is

constituted by the mutated Val80 to Lys (shown in pink).

Figure EV3. Structural comparison between LH3 and other glycosyltranferases. The

conserved aminoacids are shown as sticks; where present, Mn^{2+} cofactor and UDP-sugar are

shown as purple sphere and black sticks respectively. Protein name and related PDB ID are

indicated for each panel. Colour coding is as in Figure 1A and is maintained throughout the

structures allowing to compare the LH3 critical residues with the other structures. For additional

information on the proteins indicated in this panel refer to Table 2.

Figure EV4. Comparison of the GT domains of wild-type LH3 in ligand-bound and ligand-

free states. (A) The structure of wild-type LH3 crystallized in presence of Mn^{2+} and UDP shows

clear electron density for Mn^{2+} ($2F_o$-F_c omit electron density map shown as green mesh, contour

level 2 σ), but unexpectedly no density is present for UDP. Residue highlight and colouring as in

Figure 1A. (B) The comparative superposition of wild-type LH3 GT domain co-crystallized in

presence of Mn^{2+} and UDP (purple), and without cofactors (cyan – PDB ID: 6FXK) shows no

differences in the conformations of the side chains for the residues delimiting the GalT/GlcT

catalytic site.

Figure EV5. Superposition of the LH3 structure and the LH1 and LH2 homology models.

Superposition of the GT site of LH3 in complex with UDP-glucose (PDB ID: 6FXT) and LH1

and   LH2   homology   models   (Scietti   et   al,   2019)   (available   at

http://fornerislab.unipv.it/SiMPLOD/). Aminoacids identified as part of the LH3 catalytic site are

shown as light blue sticks, while the LH1 and LH2 residues which differs from LH3 are shown in

pink and orange respectively. UDP moiety (black lines) and Mn^{2+} cofactor (purple sphere) are

also shown from the LH3 structure.